Live Breaking News & Updates on National Medical Products Administration

Stay updated with breaking news from National medical products administration. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer

/PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes. ....

Rhui Zhou , United States , Innovent Biologics , Hana Claudin , Eli Lilly , Xianjun Yu , Sanofi Incyte , Innovent Or Company , National Medical Products Administration , American Society Of Clinical Oncology , Gastrointestinal Cancers Congress , Innovent Biologics Inc , Fudan University Shanghai Cancer Center , Prnewswire Innovent Biologics Inc , Biliary Cancer Working Group , Md Anderson Cancer Center , Clinical Oncology , Annual Meeting , Cancers Congress , Senior Vice President , Biliary Cancer Working ,

GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting

SHANGHAI and CHICAGO, June 2, 2024 /PRNewswire/ GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in ....

United States , Yu Wang , Vanesa Gregorc , Rafael Rosell , China National Medical Products Administration , American Society Of Clinical Oncology , Candiolo Cancer Institute , Genfleet Therapeutics , Clinical Oncology , National Medical Products Administration , Chief Medical Officer , Priority Review Designation , Breakthrough Therapy Designations , Thailand Business ,

Taletrectinib Yields Durable Responses in TKI Naive and Crizotinib Pretreated ROS1+ NSCLC

Taletrectinib Yields Durable Responses in TKI Naive and Crizotinib Pretreated ROS1+ NSCLC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Wei Li , Thoracic Cancer Institute , Tongji University School Of Medicine , Medical Oncology , Shanghai Pulmonary Hospital , Tongji University School , Drug Evaluation , National Medical Products Administration ,

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
thailand-business-news.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thailand-business-news.com Daily Mail and Mail on Sunday newspapers.

Li Zhang , United States , United Kingdom , International Agency For Research On Cancer , Japan National Cancer Registry , American Cancer Society , Sun Yat Sen University Cancer Center , Akeso Inc , American Society Of Clinical Oncology , National Medical Products Administration , World Health Organization , Showed Clinically Meaningful , Statistically Significant Benefit , Patients Previously Receiving , Treatment Discontinuation , Adverse Events , Oral Presentation , Manuscript Published , Neutrophil Count , Platelet Count , North America , Clinical Oncology , Annual Meeting , China In May , Breakthrough Therapy Designations , Drug Evaluation ,

Ivonescimab In Combination With Chemotherapy Approved In China By NMPA For 2L+ Egfrm NSCLC Based On Harmoni-A Clinical Trial: Positive Trend Observed ...

Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0 ....

Prnewswire Akeso Inc , National Medical Products Administration , Showed Clinically Meaningful , Statistically Significant Benefit , Patients Previously Receiving , Adverse Events , Treatment Discontinuation , Oral Presentation , Manuscript Published ,